Bacterial Cell Wall Synthesis Research Articles

Anti-biofilm and anti-adherence activity of Glm-U inhibitors

Intravascular catheters and urinary catheters are an important source of hospital-acquired infections. Many microorganisms colonize indwelling catheters, including central venous catheters (CVCs) forming biofilms and cause infections that are difficult to treat. Although various methods have been employed to reduce biofilms, enzymes involved in bacterial cell wall synthesis could provide novel targets for the development of anti-biofilm agents. N-Acetylglucosamine-1-phosphate uridyltransferase (GlmU) is an essential enzyme in aminosugars metabolism and catalyzes the formation of uridine-diphospho-N-acetylglucosamine (UDP-GlcNAc), an important precursor in the peptidoglycan and lipopolysaccharide biosynthesis of Gram-positive and Gram-negative bacteria. Previous study has been conducted on the anti-biofilm effect of GlmU inhibitors such as N-ethyl maleimide (NEM) and NEM analogs along with a cationic polypeptide protamine sulfate (PS), which enhanced its anti-biofilm activity. The present study aimed at finding the effect of sub-inhibitory concentrations of N-ethyl maleimide (NEM) and protamine sulfate (PS) on the biofilms produced by Pseudomonas aeruginosa and Enterococcus spp. isolated from cases of catheter-associated UTI as well as Klebsiella pneumoniae and Staphylococcus aureus isolated from cases of catheter-related bloodstream infections (CRBSI). In order to enhance the activity of NEM and to develop a broad-spectrum anti-microbial composition, NEM (50 μg/ml) was combined with protamine sulfate (50 μg/ml) and tested for anti-biofilm activity using a standard quantitative biofilm assay method. It was observed that NEM had no effect on the biofilm produced by Pseudomonas aeruginosa as well as by Enterococcus spp. NEM also caused a significant decrease in biofilm production by Staphylococcus aureus while it had no effect on the biofilm produced by Klebsiella pneumoniae. There was a significant synergistic inhibitory effect on Staphylococcus aureus and Enterococcus spp., whereas Pseudomonas aeruginosa and Klebsiella pneumoniae remained unaffected. Combination of GlmU inhibitor-plus-protamine sulfate failed to significantly reduce bacterial adherence of Pseudomonas aeruginosa and Klebsiella pneumoniae to catheter and cannula pieces, respectively. We found that the GlmU inhibitor was mainly effective in preventing the adherence and biofilm formation by gram-positive organisms. The combination of NEM and protamine sulfate may, therefore, be tried as anti-infective coatings for medical devices such as catheters and cannulas, and thus help in overcoming microbial resistance in the current era of increasing device-associated hospital infections.

ATLAS Trials: Efficacy And Safety Of Telavancin Compared With Vancomycin For The Treatment Of Skin Infections

Telavancin is an injectable lipoglycopeptide that is bactericidal in vitro against staphylococci, streptococci and vancomycin-susceptible enterococci. Telavancin inhibits bacterial cell wall synthesis by interfering with the synthesis of peptidoglycan, and binds to the bacterial membrane and disrupts membrane barrier function. The Assessment of Telavancin in cSSSI (ATLAS) program, comprising of two Phase III clinical trials, demonstrated noninferiority of telavancin to vancomycin for the treatment of complicated skin and skin-structure infections including infections due to methicillin-resistant Staphylococcus aureus (MRSA). Among clinically evaluable patients with MRSA isolated at baseline in the pooled study population, the clinical cure rate was 87.0% (208 out of 239) for patients treated with telavancin and 85.9% (225 out of 262) for patients treated with vancomycin. The most common telavancin treatment-emergent adverse events were taste disturbance, nausea, vomiting and foamy urine. Renal adverse events occurred in 3% of telavancin-treated patients and 1% of vancomycin-treated patients. Telavancin is now approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin-structure infections.

β-Lactam and glycopeptide antibiotics: first and last line of defense?

Most infections are caused by bacteria, many of which are ever-evolving and resistant to nearly all available antibiotics. β-Lactams and glycopeptides are used to combat these infections by inhibiting bacterial cell-wall synthesis. This mechanism remains an interesting target in the search for new antibiotics in light of failed genomic approaches and the limited input of major pharmaceutical companies. Several strategies have enriched the pipeline of bacterial cell-wall inhibitors; examples include combining screening strategies with lesser-explored microbial diversity, or reinventing known scaffolds based on structure-function relationships. Drugs developed using novel strategies will contribute to the arsenal in fight against the continued emergence of bacterial resistance.

An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic

Telavancin is an intravenous lipoglycopeptide antibiotic active against many Gram-positive pathogens via inhibition of bacterial cell wall synthesis and disruption of bacterial membrane function.Non-compartmental pharmacokinetic parameters of telavancin (clearance [Cl], steady-state volume of distribution [Vss], area under the concentration curve [AUC], and elimination half-life [t1/2]) were determined for five preclinical species (mice, rats, rabbits, dogs, and monkeys). Interspecies scaling was applied to predict the corresponding parameters in humans and compare retrospectively with observed values.Plasma concentrations of single doses of telavancin declined monoexponentially in all species with half-lives between 1.2 and 2.4 h. The pharmacokinetics of telavancin was demonstrated to be dose-proportional in rabbits and gender-independent in monkeys.Application of the simple allometric equation (Y = aWb) resulted in a good correlation between predicted and observed values of Vss in humans. Application of a modified allometric equation that includes brain weight (Cl × BW = aWb) resulted in a good correlation between predicted and observed values of Cl, AUC, and t1/2 in humans.These data suggest that interspecies scaling may be useful to predict pharmacokinetic parameters of telavancin in humans.

Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species

In recent years, vancomycin has received appreciable attention as an antibiotic drug of last resort. The generally accepted mechanism entails interference with bacterial cell wall synthesis. There is negligible attention to other modes, even though drug action is often multifaceted. This review provides a hypothesis for an additional mechanism of antibacterial action based on the polyphenol residue in the glycopeptide. The functionalities present are monophenol, resorcinol and hydroxybiphenyl, all of which have the potential to produce electron transfer (ET) metabolites capable of generating reactive oxygen species (ROS) and oxidative stress (OS). Considerable literature is presented in support of the thesis. Drug toxicity is rationalized based on the fundamental approach to vancomycin action. This review represents another example in support of the prior ET-ROS-OS unifying mechanism for anti-infective and toxic action. Novel insight may aid in improved drug design.

Global transcriptome analysis of the Escherichia coli O157 response to Houttuynia Cordata Thunb

Houttuynia Cordata Thunb (HCT; Saururaceae), known as ‘Eosungcho’ in Korea, has been traditionally used for antibiotic treatment and has proved its effect through clinical demonstrations. In spite of it s being used quite frequently in traditional prescriptions because of its superior antibiotic effect, HCT’s molecular mechanisms on its antibiotic effect have not been understood. Hence, this is the first study about HCT’s antibiotic mechanisms at the molecular level. HCT was extracted to acquire the fractions, then inoculated to confirm its antibiotic effect toward the bacteria Escherichia coli O157:H7 (E. coli O157:H7; ATCC 43894) through the disc diffusion method. The antibacterial efficacy of HCT was measured by diameter of cleared zone. Thereafter, we isolated the RNA of affected cells and analyzed it’s expressions through the microarray. To confirm the accuracy of the acquired data, RT-PCR was carried out. Results from this study indicate that E. coli O157:H7 exposures to HCT fractions, a number of genes that have been related to the synthesis of bacterial cell wall are downregulated, while some of the cell wall synthesis inhibitory genes are upregulated. Both results indicate that HCT fractions inhibit cell wall synthesis as like as β-lactam antibiotics. Furthermore, a few genes that have a critical role to DNA replication are downregulated. These genes, including folA, are closely related to the folate biosynthesis. Remarkable abnormal regulations that show antibiotic resistance activity of the E. coli O157: H7 are found, and are seem to be closely linked to the multidrug efflux pumps, especially upregulation of marRAB operon. The results of this study improve our understanding of the mode of action of HCT on E. coli O157:H7 and may show the usefulness of HCT fractions in the antibacterial treatment.

Modes of bacterial cell wall synthesis: combining localization analysis and protein‐protein interactions

In rod‐shaped bacteria, a complex of morphogenetic proteins coordinates cell wall biosynthesis during both lateral growth and division. One subset of these proteins (MreBCD) guides lateral synthesis whereas another group (FtsZQW, etc.) coordinates septum formation. We have found that FtsW, an integral membrane protein in Caulobacter crescentus, plays a novel dual role in both processes by interacting with critical components and regulators of peptidoglycan (PG) synthesis. Localization studies show that MreB actin cables collapse to irregular foci along the cell length upon FtsW ablation. This is mirrored by nearly identical changes in nascent PG synthesis, as measured by PG‐precursor labeling. Lateral patterns of PG synthesis, however, were uninterrupted by depletion of the essential cell division protein, FtsZ. Additionally, FtsW interacts with MreB actin and other morphogenetic complex components as inferred by two‐hybrid analysis. Our studies indicate that cell elongation may occur through two distinct modes of PG synthesis: (1) evenly distributed lateral synthesis directed by FtsW, and (2) new synthesis emanating from concentrated foci, directed by FtsZ. We hypothesize that FtsW and FtsZ interact with morphogenetic proteins in distinct functional ways, resulting in two discrete mechanisms of cell wall growth.

Beta-lactam antibiotics: from antibiosis to resistance and bacteriology.

This review focuses on the era of antibiosis that led to a better understanding of bacterial morphology, in particular the cell wall component peptidoglycan. This is an effort to take readers on a tour de force from the concept of antibiosis, to the serendipity of antibiotics, evolution of beta-lactam development, and the molecular biology of antibiotic resistance. These areas of research have culminated in a deeper understanding of microbiology, particularly in the area of bacterial cell wall synthesis and recycling. In spite of this knowledge, which has enabled design of new even more effective therapeutics to combat bacterial infection and has provided new research tools, antibiotic resistance remains a worldwide health care problem.

Comparative QSAR studies of nitrofuranyl amide derivatives using theoretical structural properties

The global increase in multidrug-resistant Mycobacterium tuberculosis strains and intolerance of first-line anti-tuberculosis drugs may cause major health problems and necessitate modification of the structural therapy regimen. In an ongoing effort to develop new and potent anti-tuberculosis agents, a series of nitrofuranyl amides were subjected to quantitative structure–activity relationship (QSAR) analysis using various feature selection methods. Nitrofuranyl amide derivatives with good therapeutic indices are known to inhibit an enzyme responsible for bacterial cell-wall synthesis and act as novel mycobacterial inhibitors. Successful implementation of a predictive QSAR model largely depends on the selection of a preferred set of molecular descriptors that can signify the chemical–biological interaction. Genetic algorithm (GA), simulated annealing and stepwise regression are applied as variable selection methods for an effective comparison and model development. The results of two-dimensional QSAR showed that a combination of topological indices, hydrophobic properties and autocorrelation descriptors of different atomic properties could be explored to design potent anti-tubercular inhibitors. Further analysis using three-dimensional QSAR technique identifies a suitable model obtained by GA-partial least square method leading to anti-tubercular activity prediction. The influences of steric and electrostatic field effects generated by the contribution plot are analysed and discussed. Both two- and three-dimensional QSAR analyses of such derivatives provide important structural insights for designing potent anti-tuberculosis drugs.

Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic Tigecycline

Persistence of tissue spirochetes of Borrelia burgdorferi as helices and round bodies (RBs) explains many erythema-Lyme disease symptoms. Spirochete RBs (reproductive propagules also called coccoid bodies, globular bodies, spherical bodies, granules, cysts, L-forms, sphaeroplasts, or vesicles) are induced by environmental conditions unfavorable for growth. Viable, they grow, move and reversibly convert into motile helices. Reversible pleiomorphy was recorded in at least six spirochete genera (>12 species). Penicillin solution is one unfavorable condition that induces RBs. This antibiotic that inhibits bacterial cell wall synthesis cures neither the second "Great Imitator" (Lyme borreliosis) nor the first: syphilis. Molecular-microscopic techniques, in principle, can detect in animals (insects, ticks, and mammals, including patients) helices and RBs of live spirochetes. Genome sequences of B. burgdorferi and Treponema pallidum spirochetes show absence of >75% of genes in comparison with their free-living relatives. Irreversible integration of spirochetes at behavioral, metabolic, gene product and genetic levels into animal tissue has been documented. Irreversible integration of spirochetes may severely impair immunological response such that they persist undetected in tissue. We report in vitro inhibition and destruction of B. burgdorferi (helices, RBs = "cysts") by the antibiotic Tigecycline (TG; Wyeth), a glycylcycline protein-synthesis inhibitor (of both 30S and 70S ribosome subunits). Studies of the pleiomorphic life history stages in response to TG of both B. burgdorferi and Treponema pallidum in vivo and in vitro are strongly encouraged.

MurF Inhibitors with Antibacterial Activity: Effect on Muropeptide Levels

MurF catalyzes the last cytoplasmic step of bacterial cell wall synthesis and is essential for bacterial survival. Our previous studies used a pharmacophore model of a MurF inhibitor to identify additional inhibitors with improved properties. We now present the characterization of two such inhibitors, the diarylquinolines DQ1 and DQ2. DQ1 inhibited Escherichia coli MurF (50% inhibitory concentration, 24 microM) and had modest activity (MICs, 8 to 16 microg/ml) against lipopolysaccharide (LPS)-defective E. coli and wild-type E. coli rendered permeable with polymyxin B nonapeptide. DQ2 additionally displayed activity against gram-positive bacteria (MICs, 8 to 16 microg/ml), including methicillin (meticillin)-susceptible and -resistant Staphylococcus aureus isolates and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium isolates. Treatment of LPS-defective E. coli cells with >or=2x MIC of DQ1 resulted in a 75-fold-greater accumulation of the MurF substrate compared to the control, a 70% decline in the amount of the MurF product, and eventual cell lysis, consistent with the inhibition of MurF within bacteria. DQ2 treatment of S. aureus resulted in similar effects on the MurF substrate and product quantities. At lower levels of DQ1 (<or=1x MIC), the level of accumulation of the substrate was less pronounced (15-fold greater compared to the amount for the control). However, a 50% increase in the amount of the MurF product compared to the control was reproducibly observed, consistent with the possible upregulation of muropeptide biosynthesis upon partial inhibition of this pathway. The overexpression of cloned MurF appeared to partly alleviate the DQ1-mediated inhibition of muropeptide synthesis. The identification of MurF inhibitors such as DQ1 and DQ2 that disrupt cell wall biosynthesis suggests that MurF remains a viable target for an antibacterial agent.

CsiA is a bacterial cell wall synthesis inhibitor contributing to DNA translocation through the cell envelope

Conjugation is a widely spread mechanism allowing bacteria to adapt and evolve by acquiring foreign DNA. The chromosome of Lactococcus lactis MG 1363 contains a 60 kb conjugative element called the sex factor capable of high-frequency DNA transfer. Yet, little is known about the proteins involved in this process. Comparative genomics revealed a close relationship between the sex factor and elements found in Gram-positive pathogenic cocci. Among the conserved gene products, CsiA is a large protein that contains a highly conserved domain (HCD) and a C-terminal cysteine, histidine-dependent amidohydrolases/peptidases (CHAP) domain in its C-terminal moiety. Here, we show that CsiA is required for DNA transfer. Surprisingly, increased expression of CsiA affects cell viability and the cells become susceptible to lysis. Point mutagenesis of HCD reveals that this domain is responsible for the observed phenotypes. Growth studies and electron microscope observations suggest that CsiA is acting as a cell wall synthesis inhibitor. In vitro experiments reveal the capacity of CsiA to bind d-Ala-d-Ala analogues and to prevent the action of penicillin binding proteins. Our results strongly suggest that CsiA sequesters the peptidoglycan precursor and prevents the final stage of cell wall biosynthesis to enable the localized assembly of the DNA transfer machinery through the cell wall.

NUCLEOTIDES BINDING Class A β‐LACTAMASE FROM BACILLUS CEREUS 569/H/9

The Class A β‐lactamase from the pathogenic bacterium Bacillus cereus 569/H/9 catalyzes hydrolysis of β‐lactam antibiotics (e.g., Penicillin G), that impede the synthesis of bacterial cell wall. Although clavulanic acid is known as an inhibitor of Class A β‐lactamases, we are interested in the utility of aptamer inhibitors of Class A enzymes since they are such highly efficient and specific inhibitors of the Bacillus cereus 5/B/6 Class B enzyme. We have attempted to bind a random pool of nucleotides to the β‐lactamase using SELEX (Systematic Evolution of Ligands by EXponential enrichment) technique. We found that the random pool of nucleotides bind β‐lactamase using the electrophoretic mobility shift assay (EMSA), confirmed by both ethidium bromide staining and coomassie blue staining. After 8 rounds of SELEX, we were able to proceed with inserting the selected nucleotides into a cloning vector in order to identify nucleotide sequences. We also carried out another method for selecting aptamers using the interaction between biotin and streptavidin. After 10 rounds of SELEX, we identified the sequences that bind the β‐lactamase. Using the computer program Mfold, the secondary structures of aptamers that potentially inhibit the β‐lactamase have also been determined.

Specific Labeling of Peptidoglycan Precursors as a Tool for Bacterial Cell Wall Studies

Because of its importance for bacterial cell survival, the bacterial cell wall is an attractive target for new antibiotics in a time of great demand for new antibiotic compounds. Therefore, more knowledge about the diverse processes related to bacterial cell wall synthesis is needed. The cell wall is located on the exterior of the cell and consists mainly of peptidoglycan, a large macromolecule built up from a three-dimensional network of aminosugar strands interlinked with peptide bridges. The subunits of peptidoglycan are synthesized inside the cell before they are transported to the exterior in order to be incorporated into the growing peptidoglycan. The high flexibility of the cell wall synthesis machinery towards unnatural derivatives of these subunits enables research on the bacterial cell wall using labeled compounds. This review highlights the high potential of labeled cell wall precursors in various areas of cell wall research. Labeled precursors can be used in investigating direct cell wall-antibiotic interactions and in cell wall synthesis and localization studies. Moreover, these compounds can provide a powerful tool in the elucidation of the cell wall proteome, the "wallosome," and thus, might provide new targets for antibiotics.

Synthesis of Stable Aminoacyl‐tRNA Analogues Containing Triazole as a Bioisoster of Esters

Aminoacyl-tRNAs have important roles in a variety of biological processes, including protein synthesis by ribosomes, targeting of proteins for degradation by the proteasome, and bacterial cell wall synthesis. Here we describe the synthesis of stable aminoacyl-tRNA analogues containing 1,4- and 1,5-substituted 1,2,3-triazole rings. The procedure involves i) Cu- and Ru-catalysed cycloadditions of 3'-azidoadenosine and alkynes, which produced the 1,4 and 1,5 regioisomers of the triazoles, respectively, ii) coupling between the resulting triazole-deoxyadenosine derivatives and a deoxycytidine phosphoramidite, and iii) the enzymatic ligation of the substituted dinucleotides with a 22 nt RNA microhelix that mimics the acceptor arm of tRNA. Nucleoside and nucleotide compounds were characterized by MS spectrometry and (1)H, (31)P and (13)C NMR spectroscopy and were assayed for inhibition of FemX(Wv), an alanyltransferase essential for the formation of the peptidoglycan network of gram-positive bacterial pathogens. The low IC(50) values obtained (2 to 4 microM) indicate that the five-membered triazole rings acted as bioisosters of esters and can be used for the design of stable aminoacyl-tRNA analogues.

Aminoacyl-tRNA recognition by the FemXWv transferase for bacterial cell wall synthesis

Transferases of the Fem family catalyse peptide-bond formation by using aminoacyl-tRNAs and peptidoglycan precursors as donor and acceptor substrates, respectively. The specificity of Fem transferases is essential since mis-incorporated amino acids could act as chain terminators thereby preventing formation of a functional stress-bearing peptidoglycan network. Here we have developed chemical acylation of RNA helices with natural and non-proteinogenic amino acids to gain insight into the specificity of the model transferase FemXWv. Combining modifications in the RNA and aminoacyl moieties of the donor substrate revealed that unfavourable interactions of FemXWv with the acceptor arm of tRNAGly and with l-Ser or larger residues quantitatively accounts for the preferential transfer of l-Ala observed with complete aminoacyl-tRNAs. The main FemXWv identity determinant was identified as the penultimate base pair (G2-C71) of the acceptor arm instead of G3•U70 for the alanyl-tRNA synthetase. FemXWv tolerated a configuration inversion of the Cα of l-Ala but not the introduction of a second methyl on this atom. These results indicate that aminoacyl-tRNA recognition by FemXWv is distinct from other components of the translation machinery and relies on the exclusion of bulky amino acids and of the sequence of tRNAGly from the active site.

Inhibitory Mechanism of Novel Inhibitors of UDP-N-Acetylglucosamine Enolpyruvyl Transferase from Haemophilus influenzae

Bacterial UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) catalyzes the transfer of enolpyruvate from phosphoenolphyruvate (PEP) to uridine diphospho-N-acetylglucosamine (UNAG), which is the first step of bacterial cell wall synthesis. We identified thimerosal, thiram, and ebselen as effective inhibitors of Heamophilus influenzae MurA by screening a chemical library that consisted of a wide range of bioactive compounds. When MurA was preincubated with these inhibitors, their 50% inhibitory concentrations (IC50s) were found to range from 0.1 to 0.7 microM. In particular, thimerosal suppressed the growth of several different Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium at a concentration range of 1-2 microg/ml. These inhibitors covalently modified the cysteine residue near the active site of MurA. This modification changed the open conformation of MurA to a more closed configuration, which may have prevented the necessary conformational change from occurring during the enzyme reaction.

Telavancin: A new lipoglycopeptide for Gram-positive infections

Telavancin is a lipoglycopeptide derivative of vancomycin. Similar to vancomycin, it demonstrates activity in vitro against a variety of Gram-positive pathogens, including but not limited to methicillin-resistant Staphylococccus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). Modifications to vancomycin's structure expanded telavancin's spectrum of activity in vitro to include organisms such as glycopeptide-intermediate S. aureus (GISA), vancomycin-resistant S. aureus (VRSA) and vancomycin-resistant enterococci (VRE). However, the clinical implications of this are currently unknown. Similar to other glycopeptides, televancin binds to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus in Gram-positive organisms, resulting in inhibition of bacterial cell wall synthesis. In addition, telavancin causes depolarization of the bacterial cell membrane and increased membrane permeability. The resulting activity in vitro is rapidly bactericidal and concentration dependent, with the ratio of area under the time concentration curve to minimum inhibitory concentration (AUC/MIC) as the best predictor of activity in animal models to date. In humans, telavancin exhibits a pharmacokinetic profile that permits once-daily intravenous administration. Doses of 7.5 and 10 mg/kg/day have been studied in clinical trials. The need for dosage adjustments based on age, gender and obesity appear unnecessary. In addition, moderate hepatic impairment does not appreciably alter the pharmacokinetics of the drug. Because telavancin is extensively cleared by the kidneys, dosage adjustments will be required in patients with moderate to severe renal impairment. Published phase II and III clinical trials have shown telavancin to be comparable to standard therapy for the treatment of complicated skin and soft tissue infections. Clinical trials in the treatment of S. aureus bacteremia and hospital-acquired pneumonia are under way. Adverse effects overall appear to be mild and reversible, with taste disturbance, foamy urine, headache, procedural site pain, nausea and vomiting being the most commonly reported. However, renal toxicity was reported more frequently with telavancin than with vancomycin in two phase III clinical trials (3% versus 1%). Prolongation of the corrected QT (QTc) interval has been more common with telavancin than comparator agents, but no clinically significant electrocardiogram (ECG) changes or cardiac abnormalities have been observed to date. Although human pregnancy data is not currently available, animal data revealed limb malformations that were possibly related to telavancin therapy. Therefore, the potential teratogenicity of this agent must be considered in women who are pregnant or may become pregnant.

The Vancomycin−Nisin(1−12) Hybrid Restores Activity against Vancomycin Resistant Enterococci

Lipid II is a crucial component in bacterial cell wall synthesis [Breukink, E., et al. (1999) Science 286, 2361-2364]. It is the target of a number of important antibiotics, which include vancomycin and nisin [Breukink, E., and de Kruijff, B. (2006) Nat. Rev. Drug Discovery 5, 321-332]. Here we show that a hybrid antibiotic that consists of vancomycin and nisin fragments is significantly more active than the separate fragments against vancomycin resistant entercocci (VRE). Three different hybrids were synthesized using click chemistry and compared. Optimal spacer lengths and connection points were predicted using computer modeling.

Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics

The bacterial cell wall is mainly composed of peptidoglycan, which is a three-dimensional network of long aminosugar strands located on the exterior of the cytoplasmic membrane. These strands consist of alternating MurNAc and GlcNAc units and are interlinked to each other via peptide moieties that are attached to the MurNAc residues. Peptidoglycan subunits are assembled on the cytoplasmic side of the bacterial membrane on a polyisoprenoid anchor and one of the key components in the synthesis of peptidoglycan is Lipid II. Being essential for bacterial cell survival, it forms an attractive target for antibacterial compounds such as vancomycin and several lantibiotics. Lipid II consists of one GlcNAc-MurNAc-pentapeptide subunit linked to a polyiosoprenoid anchor 11 subunits long via a pyrophosphate linker. This review focuses on this special molecule and addresses three questions. First, why are special lipid carriers as polyprenols used in the assembly of peptidoglycan? Secondly, how is Lipid II translocated across the bacterial cytoplasmic membrane? And finally, how is Lipid II used as a receptor for lantibiotics to kill bacteria?